These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 15936743)
1. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Adorini L Cell Immunol; 2005 Feb; 233(2):115-24. PubMed ID: 15936743 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. Adorini L; Penna G; Giarratana N; Roncari A; Amuchastegui S; Daniel KC; Uskokovic M J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):437-41. PubMed ID: 15225816 [TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. Penna G; Amuchastegui S; Laverny G; Adorini L J Bone Miner Res; 2007 Dec; 22 Suppl 2():V69-73. PubMed ID: 18290726 [TBL] [Abstract][Full Text] [Related]
4. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Adorini L; Penna G Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030 [TBL] [Abstract][Full Text] [Related]
5. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988 [TBL] [Abstract][Full Text] [Related]
6. Control of autoimmune diseases by the vitamin D endocrine system. Adorini L; Penna G Nat Clin Pract Rheumatol; 2008 Aug; 4(8):404-12. PubMed ID: 18594491 [TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Adorini L Int Immunopharmacol; 2002 Jun; 2(7):1017-28. PubMed ID: 12188026 [TBL] [Abstract][Full Text] [Related]
8. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Waterhouse JC; Perez TH; Albert PJ Ann N Y Acad Sci; 2009 Sep; 1173():757-65. PubMed ID: 19758226 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. Iruretagoyena MI; Sepúlveda SE; Lezana JP; Hermoso M; Bronfman M; Gutiérrez MA; Jacobelli SH; Kalergis AM J Pharmacol Exp Ther; 2006 Jul; 318(1):59-67. PubMed ID: 16597709 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Adorini L; Penna G Hum Immunol; 2009 May; 70(5):345-52. PubMed ID: 19405173 [TBL] [Abstract][Full Text] [Related]
11. Prevention of chronic allograft rejection by Vitamin D receptor agonists. Adorini L; Amuchastegui S; Daniel KC Immunol Lett; 2005 Aug; 100(1):34-41. PubMed ID: 16054704 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. Masuyama R; Stockmans I; Torrekens S; Van Looveren R; Maes C; Carmeliet P; Bouillon R; Carmeliet G J Clin Invest; 2006 Dec; 116(12):3150-9. PubMed ID: 17099775 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Adorini L; Penna G; Fibbi B; Maggi M Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021 [TBL] [Abstract][Full Text] [Related]
14. Vitamin D resistance. Bouillon R; Verstuyf A; Mathieu C; Van Cromphaut S; Masuyama R; Dehaes P; Carmeliet G Best Pract Res Clin Endocrinol Metab; 2006 Dec; 20(4):627-45. PubMed ID: 17161336 [TBL] [Abstract][Full Text] [Related]
15. Increased apoptosis of periprostatic adipose tissue in VDR null mice. Guzey M; Jukic D; Arlotti J; Acquafondata M; Dhir R; Getzenberg RH J Cell Biochem; 2004 Sep; 93(1):133-41. PubMed ID: 15352170 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Choi M; Makishima M Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936 [TBL] [Abstract][Full Text] [Related]
17. The vitamin D receptor in cancer. Thorne J; Campbell MJ Proc Nutr Soc; 2008 May; 67(2):115-27. PubMed ID: 18412986 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Wongkham S Cancer; 2007 Jun; 109(12):2497-505. PubMed ID: 17487855 [TBL] [Abstract][Full Text] [Related]
19. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. Motrich RD; van Etten E; Depovere J; Riera CM; Rivero VE; Mathieu C J Autoimmun; 2009 Mar; 32(2):140-8. PubMed ID: 19269787 [TBL] [Abstract][Full Text] [Related]
20. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Okamura M; Takano Y; Saito Y; Yao J; Kitamura M Nephrol Dial Transplant; 2009 Oct; 24(10):3006-12. PubMed ID: 19474283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]